CORMEDIX REPORTS YEAR END 2012 FINANCIAL RESULTS Bridgewater, New Jersey

CORMEDIX REPORTS YEAR END 2012 FINANCIAL

Bridgewater, New Jersey, March 27, 2013

(Business Wire) - CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a pharmaceutical company focused on developing

and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces its financial results

for the year ended December 31, 2012.

Fourth Quarter 2012 and First Quarter 2013 Financing Developments

During the fourth quarter of 2012 and first

quarter of 2013, CorMedix:

Financial Results for the Year Ended December 31, 2012

The net loss for the year ended December

31, 2012 was $3.4 million, or ($0.30) per diluted share, compared to a net loss of $6.7 million, or ($0.59) per diluted share,

for the year ended December 31, 2011. The decrease in net loss was primarily attributable to CorMedix's decision in late

2011 to focus the majority of its resources, including its research and development efforts primarily on CE Mark approval and the

commercialization of Neutrolin (CRMD003) in Europe.

Research and Development ("R&D")

expense was $1.2 million for the year ended December 31, 2012, a decrease of $2.9 million, from $4.1 million for the year ended

December 31, 2011. The decrease in R&D was primarily attributed to CorMedix's strategic change of direction during September

2011, which is to focus primarily on CE Mark approval for Neutrolin in Europe. During the fourth quarter of 2011,

CorMedix also discontinued the development of deferiprone (CRMD001), and returned the product candidate to the licensor in December

2011. CorMedix's strategic change of direction also resulted in lower clinical research organization, manufacturing and regulatory

expenses related to the development of CRMD003 during the second quarter of 2012 and lower personnel costs as a result of its former

Chief Medical Officer ("CMO") transitioning to a part-time status and a 50% reduction of salary effective March 2012.

General and Administrative ("G&A")

expense was $1.9 million for the year ended December 31, 2012, a decrease of $1.2 million, from $3.1 million for the year ended

December 31, 2011. The decrease was primarily attributable to lower compensation and stock-based compensation expense as a result

of the separation of CorMedix's former President and Chief Executive Officer in September 2011 and the resignation of its

Chief Financial Officer/Chief Operating Officer in April 2012 and lower expenses related to investor relations.

Other income was approximately $30,000 for

the year ended December 31, 2011, which represented a research and development funding reimbursement from the State of New York

research and development tax refund program. No other income was recognized for the year ended December 31, 2012.

Interest income was approximately $2,000

for the year ended December 31, 2012, a decrease of approximately $10,000, from approximately $12,000 for the year ended December

31, 2011. The decrease was attributable to having lower interest-bearing cash balances during the year ended December 31, 2012

as compared to the year ended December 31, 2011.

Interest expense was approximately $383,000

for the year ended December 31, 2012. No interest expense was recognized for the year ended December 31, 2011. The interest expense

charges consisted primarily of a beneficial conversion feature charge of approximately $279,000 related to the senior convertible

notes and warrants issued in September and November 2012 in the aggregate principal amount of $1,324,000, amortization of deferred

financing fees of approximately $77,000 and accrued interest of approximately $27,000 related to the senior convertible notes.

At December 31, 2012, CorMedix had cash

and cash equivalents of $0.8 million, compared to $2.0 million at December 31, 2011. CorMedix believes its currently available

cash and cash equivalents, including the proceeds from its February 2013 sale of Series A non-voting convertible preferred stock,

will be sufficient to fund its operations into the second quarter of 2013, and will need additional financing to launch Neutrolin

and thereafter until it can achieve profitability, if ever.

Management Commentary

Commenting on year-end results, CorMedix

Chief Executive Officer, Randy Milby, stated, "We are pleased with the progress we made during 2012 with Neutrolin

towards CE Marking approval, which is expected by the end of the first half of 2013. We continue to plan with our marketing partner,

MKM Co-Pharma GmbH, as well as seek additional partners and distributors, for the launch of Neutrolin for the prevention

of catheter related bloodstream infections and maintenance of catheter patency in hemodialysis and non-dialysis patients in Europe

in 2013, subject to receiving CE Mark approval in Europe."

A conference call will be held on Thursday,

March 28, 2013 at 8:30 a.m. Eastern, hosted by Randy Milby, Chief Executive Officer and Richard M. Cohen, Chief Financial Officer

of CorMedix. In order to participate in the conference call, please call 1-866-866-1333 (U.S.), 1-404-260-1421 (outside the U.S.),

reference: CorMedix.

CorMedix Inc. is a pharmaceutical company that seeks to in-license,

develop and commercialize therapeutic products for the prevention and treatment of cardiac and renal dysfunction, also known as

cardiorenal disease, specifically in the dialysis and non-dialysis areas. CorMedix's most advanced product candidate is Neutrolin

(CRMD003) for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled,

cuffed, central venous catheters used for vascular access in hemodialysis patients. Please see www.cormedix.com for additional

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's

expectations, beliefs, goals, plans or CorMedix's prospects and future financial position should be considered forward-looking.

Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors,

including: obtaining regulatory approvals to conduct clinical trials and to commercialize CorMedix's product candidates, including

CE Marking for Neutrolin in Europe; CorMedix's ability

to maintain its listing on the NYSE MKT; the risks

and uncertainties associated with CorMedix's ability to manage its limited cash resources and obtain additional financing

to support CorMedix's research and development and clinical activities and operations; the outcome of clinical trials of CorMedix's

product candidates and whether they demonstrate these candidates' safety and effectiveness; CorMedix's ability to enter into and

maintain collaborations with third parties for its development programs; CorMedix's dependence on its collaborations and its license

relationships; achieving milestones under CorMedix's collaborations; CorMedix's dependence on preclinical and clinical investigators,

preclinical and clinical research organizations, manufacturers and consultants; and

protecting the intellectual property developed by or licensed to CorMedix. These and other risks are described in greater

detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov

or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking

statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend

to update these forward-looking statements, except as required by law.

Chief Executive Officer

(A Development Stage Company)

Condensed Statements Of Operations

Condensed Balance Sheet